Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Jul 29, 2014, 16:15 ET from Alexza Pharmaceuticals, Inc.

MOUNTAIN VIEW, Calif., July 29, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is participating in two healthcare conferences during the third quarter, the 2014 Avondale Partners Healthcare 1-1 Conference and the Morgan Stanley Global Healthcare 2014 Conference.  Alexza's corporate presentation will be webcast live from the Morgan Stanley Conference.  The details on each event are below:

  • 2014 Avondale Partners Healthcare 1-1 Conference, Monday, August 11, 2014 in Boston, MA.  The format is limited to one-on-one meetings with investors and there is no webcast from this conference.
  • Morgan Stanley Global Healthcare Conference 2014, September 8 - 10, 2014 in New York, NY.  The Company's corporate presentation will be on Tuesday, September 9th at 9:10 am ET.  The webcast of the presentation may be accessed from the Investor Relations section of the Alexza Pharmaceuticals website at  A replay of the Morgan Stanley Healthcare Conference presentation will be available for 30 days on the Investor Relations section of Alexza's website approximately 24 hours after the presentation. 

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's products are based on the Staccato® system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.

ADASUVE® is Alexza's first commercial product and it has been approved for sale by the U.S. Food and Drug Administration, and the European Commission.  Teva Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the U.S.  Ferrer is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries.

ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE, estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Logo -

SOURCE Alexza Pharmaceuticals, Inc.